Bone marrow aspirate, processed adipose tissue, and a cryopreserved umbilical cord tissue vial side by side on a laboratory bench

Wharton's Jelly vs. Bone Marrow vs. Adipose Stem Cells: A Sourcing Comparison for Licensed Practices

Sourcing Comparison · MSC Tissue Sources · For Licensed Professionals

Wharton's Jelly vs. Bone Marrow vs. Adipose Stem Cells: A Sourcing Comparison for Licensed Practices

By Stem Nova Network | October 2026 | 8 min read | For licensed medical professionals only

Bone marrow and adipose (fat) cells are collected from the patient in a same-day procedure, while Wharton's jelly cells come from donated umbilical cord tissue and arrive as a lot-tested, frozen vial. All three are sources of mesenchymal stem cells (MSCs) and are defined by the same laboratory criteria. They differ in who the donor is, how the cells are collected and processed, how many MSCs are present, and what documentation comes with them.

Practices weighing bone marrow concentrate (BMAC) or adipose-derived options against a purchased umbilical cord tissue product are usually comparing workflows as much as cells. This guide lays out the sourcing differences side by side, without claims about what any product does, so you can evaluate each option on logistics, documentation, and consistency.

Important: This guide compares tissue sources, collection, processing, and documentation only. It makes no claims about the effects of any cell product and does not provide dosing, procedural, or treatment guidance. hUCT-MSC products are individualized and not FDA-approved; use is clinician-directed, and patients should consult their primary care provider.

The Three Sources at a Glance

Factor Bone marrow (BMAC) Adipose (fat) Wharton's jelly (hUCT-MSC)
Donor The patient (autologous) The patient (autologous) A screened donor (allogeneic)
Tissue source Bone marrow aspirate, typically from the iliac crest Lipoaspirate from a liposuction-type harvest Umbilical cord tissue donated after a healthy, full-term birth
Collection for the patient Aspiration procedure on the day of service Harvest procedure on the day of service None; the vial arrives ready
Donor age The patient's age The patient's age Neonatal tissue
Processing Centrifuged at the point of care into a concentrate Processed at the point of care (mechanical or other methods) Isolated, cultured, tested, and cryopreserved before shipping
MSC content A small fraction of a mixed cell population; varies by patient Higher MSC frequency per gram than marrow; varies by patient Labeled cell count per vial, confirmed per lot
Documentation Usually none beyond in-clinic records Usually none beyond in-clinic records Lot-specific Certificate of Analysis
Equipment Aspiration and centrifuge kits Harvest and processing kits Liquid nitrogen (preferred) or −80 °C cryo freezer

What Makes a Cell an MSC, Whatever the Source

The International Society for Cellular Therapy (ISCT) defines mesenchymal stromal cells by three minimal laboratory criteria, regardless of where they come from (Dominici et al., 2006):

  • Plastic adherence under standard culture conditions.
  • Surface markers: at least 95% of cells express CD73, CD90, and CD105, and no more than 2% express CD45, CD34, CD14 or CD11b, CD79a or CD19, and HLA-DR.
  • Differentiation in the lab into bone, cartilage, and fat lineages.

Bone marrow, adipose, and Wharton's jelly MSCs can all meet these criteria. The meaningful sourcing differences are in collection, cell numbers, donor age, processing, and documentation.

Bone Marrow Concentrate (BMAC)

BMAC is made from the patient's own bone marrow, aspirated and centrifuged at the point of care into a concentrate. It is not a purified MSC product. The concentrate contains many cell types, including blood-forming cells, and MSCs make up a small fraction of the nucleated cells. Classic research estimated bone marrow MSCs at roughly 0.001% to 0.01% of nucleated cells (Pittenger et al., 1999).

Sourcing considerations

  • Patient procedure: requires an aspiration on the day of service.
  • Variability: MSC content varies from patient to patient. Published research has reported that MSC numbers and characteristics in marrow change with donor age (Stolzing et al., 2008).
  • Documentation: no lot COA. Any cell count depends on what the clinic measures in-house.
  • Workflow: collection, processing, and use happen in one visit, so the schedule and staffing must allow for it.

Adipose-Derived Cells

Adipose options start with a harvest of the patient's own fat. Depending on the method, the tissue is processed mechanically into a micro-fragmented product or processed further into what is often called the stromal vascular fraction (SVF). Adipose tissue has been reported to contain a substantially higher frequency of MSC-like cells per gram than bone marrow (Zuk et al., 2002), but the final content still varies by patient and by processing method.

Sourcing considerations

  • Patient procedure: requires a harvest on the day of service.
  • Processing method matters: mechanical and enzymatic methods produce different products and are treated differently by regulators. Confirm the regulatory position of any processing kit with counsel.
  • Variability: yield depends on the patient, the harvest, and the device.
  • Documentation: no lot COA; in-clinic records only.

Wharton's Jelly (hUCT-MSC)

Wharton's jelly is the gelatinous connective tissue surrounding the vessels of the umbilical cord. Cords are donated after a healthy, full-term birth under informed consent, and the donor is screened under FDA donor eligibility requirements (21 CFR Part 1271, Subpart C). Cells are isolated from the tissue, cultured, tested, and cryopreserved, then shipped frozen as a vial with a stated cell count. Learn more in What Is Wharton's Jelly?

Sourcing considerations

  • No patient harvest: the vial arrives ready, so there is no aspiration or liposuction step in the visit.
  • Neonatal source tissue: donor age is the same for every lot, rather than the patient's own age.
  • Lot documentation: a Certificate of Analysis reports sterility, endotoxin, mycoplasma, cell count, post-thaw viability, and marker expression for each lot.
  • Cold chain: vials ship on dry ice and must go straight into liquid nitrogen (preferred) or a −80 °C cryo freezer. See our Cold-Chain Receiving Guide.
  • Regulatory status: hUCT-MSC products are individualized and not FDA-approved. State law also varies; see our state-by-state guide.
The core trade-off: Autologous options (BMAC and adipose) use the patient's own tissue but add a collection procedure and vary from patient to patient. A purchased Wharton's jelly product removes the harvest step and comes with lot documentation, but it is an allogeneic, individualized product that is not FDA-approved and requires cold storage. Which fits a practice depends on its workflow, equipment, documentation needs, and regulatory review.

Questions to Ask Before Choosing a Source

1

What will you document, and how?

A purchased product should come with a lot-specific COA. For autologous options, decide what you will measure in-house and how you will record it.

2

Does your workflow support a same-day harvest?

BMAC and adipose add a collection procedure, kit costs, and chair time to every visit.

3

Do you have the right storage?

Cryopreserved vials require liquid nitrogen or a −80 °C cryo freezer and someone to receive deliveries.

4

How is the donor screened and the tissue sourced?

For allogeneic products, ask about donor eligibility screening, viral panel, and the tissue source establishment.

5

Have you reviewed the regulatory position?

Federal rules and state laws differ by tissue source and processing method. Review any program with qualified counsel.

Stem Nova Network's hUCT-MSC Vials

Stem Nova Network supplies 25M and 10M hUCT-MSC vials to licensed professionals. For the 25M: Wharton's jelly tissue source from AATB-accredited establishment with this tissue category within scope of accreditation. Both vials come from first-pregnancy donors, are cultured in xeno-free, FBS-free 3D bioreactor systems, are cryopreserved DMSO-free, and carry 97% post-thaw viability with a lot-specific, dual-lab Certificate of Analysis. Manufacturing takes place in the USA in an FDA-registered facility that is cGTP-compliant (21 CFR Part 1271). See Wholesale Stem Cells for specifications.

Review the Documentation Before You Decide

Licensed practices can view pricing and lot-specific COAs after credential verification. Most applications are reviewed within 24 hours.

Apply for Wholesale Access → Contact Our Team

Frequently Asked Questions

What is the difference between Wharton's jelly and bone marrow stem cells?

Bone marrow cells come from the patient's own marrow, collected by aspiration and concentrated at the point of care; MSCs are a small fraction of that concentrate. Wharton's jelly cells come from donated umbilical cord tissue and are isolated, cultured, tested, and cryopreserved before shipping as a vial with a stated cell count and a lot-specific COA.

Is BMAC the same as a stem cell product?

No. Bone marrow aspirate concentrate is a mixed population of cells from the patient's marrow. It contains MSCs, but they are a small fraction of the nucleated cells, and the amount varies by patient. It is not a purified or counted MSC product.

Does adipose tissue have more stem cells than bone marrow?

Published research has reported a substantially higher frequency of MSC-like cells per gram of adipose tissue than in bone marrow. Final content still depends on the patient, the harvest, and the processing method.

Is umbilical cord blood the same as Wharton's jelly?

No. Cord blood is the blood in the umbilical vessels and is a source of blood-forming cells. Wharton's jelly is the connective tissue around those vessels and is a source of mesenchymal stem cells.

Are Wharton's jelly stem cells FDA-approved?

No. hUCT-MSC products are individualized and not FDA-approved. Use is clinician-directed, and patients should consult their primary care provider. State laws governing stem cell use also vary.

What documentation should come with a purchased stem cell vial?

A lot-specific Certificate of Analysis covering sterility, endotoxin, mycoplasma, cell count, post-thaw viability, and surface marker expression, plus donor screening and viral panel results. Dual-lab verification means two separate reports from two different facilities.

Related Resources

References

  • Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317.
  • Pittenger MF, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143–147.
  • Zuk PA, et al. Human adipose tissue is a source of multipotent stem cells. Molecular Biology of the Cell. 2002;13(12):4279–4295.
  • Stolzing A, et al. Age-related changes in human bone marrow-derived mesenchymal stem cells. Mechanisms of Ageing and Development. 2008;129(3):163–173.
  • U.S. Food and Drug Administration. 21 CFR Part 1271 — Human Cells, Tissues, and Cellular and Tissue-Based Products.
Regulatory Notice: This article is for informational purposes only and does not constitute clinical guidance or legal advice. It compares tissue sources and documentation and makes no claims about the effects of any cell product. hUCT-MSC products are individualized, not FDA-approved, and clinician-directed; patients should consult their primary care provider. These products are not FDA-approved drugs or therapeutic agents and are not intended to diagnose, treat, cure, or prevent any disease or condition. Stem Nova Network does not provide dosing, procedural, or protocol guidance. All clinical decisions are the sole responsibility of the licensed practitioner in accordance with applicable federal and state regulations. Stem Nova Network is a DBA of D1D Enterprises, Inc.
Back to Exosome & Stem Cell Resources for Medical Professionals